"Among our customers, we note a heightened awareness of preventative safety practices. Also, OURAY see a lot of growth in those exceedingly hazardous chemicals such as fluoridated and brominated materials."
HEAD OF DRUG SUBSTANCE (SR), HEAD OF DRUG DELIVERY & PRODUCT (PS), EVONIK HEALTH CARE
"The US leads innovation, so if you are not heavily invested there in pharma, you are in trouble. Lots of our clients are shifting their production from Asia, so the US will remain critical to Evonik Health Care’s growth."
"We want to pioneer a commodity utility approach for needed areas of pharmaceutical manufacturing, and make that available as a sustainable platform that any country can start with and innovate from."
"Experienced CDMOs can provide companies with access to new formulation and technology methods that improve the bioavailability of difficult-to-formulate compounds."
"Companies should be ready to address hostile short-selling and unsolicited takeover bids, develop rapid responses to special meetings and activist demands, and vigorously engage with institutional shareholders, proxy advisory firms, and potential regulators."
"The expansion will allow Prince to more than double its headcount, increase manufacturing capacity, and offer additional ready-to-use products and sterilization services to the market."
PRESIDENT AND CEO, PENNSYLVANIA BIOTECHNOLOGY CENTER (PABC)
"I hope to continue seeing companies coming from across the country contributing to the significant growth of the greater Philadelphia area in life sciences."
Mexico's chemical industry faces challenges in securing a reliable feedstock supply and maintaining global competitiveness. A shift towards sustainable energy and local production could provide long-term growth opportunities, and some sectors are booming, including Mexico's dynamic chemical distribution market.